Understanding the Class Action Lawsuit Against DexCom, Inc.
DexCom, Inc. (NASDAQ: DXCM) is currently facing a major class action securities lawsuit spearheaded by the legal team at Levi & Korsinsky, LLP. This lawsuit stems from financial announcements that have raised serious concerns among investors and analysts.
Who is Affected by This Lawsuit?
This lawsuit aims to protect investors who may have been impacted by alleged securities fraud that occurred between January and July of a specific fiscal year. If you suffered any losses in your investments during this time frame, you could be eligible to participate in this case.
Details of the Securities Fraud Allegations
Investors have raised alarms following DexCom's financial report that was released at the end of July. The company revealed disappointing earnings for the second quarter and lowered its revenue forecasts for the entire fiscal year. This bleak update had a direct effect on the company's stock, which fell dramatically in just one day, illustrating how these revelations shook investor confidence.
Implications of the Price Drop
On July 25, DexCom's stock was valued at $107.85 per share, but the following day, it plummeted to $64.00. This staggering 40.66% drop demonstrates the significant financial harm caused by the company's disclosures regarding its weaknesses and unmet business targets.
Steps to Take if You’ve Experienced Losses
If you are one of the investors who incurred losses in DexCom during the specified period, knowing the next steps is vital. You have until a defined deadline to request your status as a lead plaintiff, although you don’t need to be a lead plaintiff to partake in any financial recovery.
No Financial Risk Involved
One of the most comforting aspects of joining this lawsuit is that there are no upfront costs for eligible class members. If you meet the criteria, you could receive compensation without having to pay any out-of-pocket expenses, making this an attractive opportunity for affected investors.
Why Choose Levi & Korsinsky?
Levi & Korsinsky offers over 20 years of experience in representing investors in complex securities litigation. Their impressive history of securing large settlements for shareholders showcases their commitment to their clients. With more than 70 dedicated professionals, they are well-prepared to handle the complexities of such cases, ensuring the protection of investor rights.
Contact Information for Interested Investors
If you want to learn more or discuss your situation, feel free to reach out to Levi & Korsinsky. Investors can contact Joseph E. Levi, Esq. via email or phone for expert legal assistance.
Address:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: jlevi@levikorsinsky.com
Phone: (212) 363-7500
Frequently Asked Questions
What is the reason for the class action lawsuit against DexCom?
The lawsuit aims to recover losses for investors affected by securities fraud claims linked to financial disclosures over several months.
What was the impact of DexCom's announcements on its stock price?
The company's stock experienced a significant drop of approximately 40.66%, declining from $107.85 to $64.00 just one day after the disappointing guidance was issued.
How can I participate in the class action lawsuit?
To join the lawsuit, you can contact Levi & Korsinsky, and they will guide you through the necessary steps and provide any details you might need.
Are there any fees to participate in the lawsuit?
No, taking part in the class action lawsuit does not involve any out-of-pocket costs; it is entirely free for eligible investors.
Why is Levi & Korsinsky a good choice for this lawsuit?
With a strong track record of securing significant settlements and a team full of experienced attorneys, they are well-prepared to successfully handle securities litigation.
